Literature DB >> 26046454

Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation.

Yong-Oon Ahn1,2, Matthew A Weeres1, Marie-Luise Neulen1, Jahyang Choi2, Seong-Ho Kang2, Dae Seog Heo2,3, Rachel Bergerson1, Bruce R Blazar1, Jeffrey S Miller4, Michael R Verneris1.   

Abstract

Death receptor 3 (DR3, TNFRSF25) is expressed by activated lymphocytes and signaling by its ligand, TL1A, enhances cytokine expression and proliferation. Recent studies show that DR3 is also present on murine type 2 innate lymphoid cells (ILC2s). Here, we show that DR3 is expressed by IL-22-producing human group 3 innate lymphoid cells (ILC3s). Stimulation of ILC3s with exogenous TL1A alone had no impact on cytokine production or proliferation. Addition of TL1A to IL-1β + IL-23 significantly enhanced the amount IL-22 produced by ILC3s as well as the percentage IL-22- and IL-8-producing cells. Addition of TL1A to IL-1β + IL-23 also augmented ILC3 proliferation. Mechanistically, this occurred through the upregulation of CD25 and responsiveness to IL-2 stimulation. The combination of TL1A, IL-1β+ IL-23, and IL-2 expanded ILC3s while IL-1β+ IL-23 did not increase proliferation above controls. After 2 weeks of expansion, ILC3s maintained their phenotype, transcription factor expression, and function (IL-22 production). These findings identify DR3 as a costimulatory molecule on ILC3s that could be exploited for ex vivo expansion and clinical use.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  DR3; Human; IL-22; ILC3; TL1A

Mesh:

Substances:

Year:  2015        PMID: 26046454      PMCID: PMC4595159          DOI: 10.1002/eji.201445213

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

1.  Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone.

Authors:  Elke Scandella; Beatrice Bolinger; Evelyn Lattmann; Simone Miller; Stéphanie Favre; Dan R Littman; Daniela Finke; Sanjiv A Luther; Tobias Junt; Burkhard Ludewig
Journal:  Nat Immunol       Date:  2008-04-20       Impact factor: 25.606

2.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

Review 3.  Human innate lymphoid cells.

Authors:  Mette D Hazenberg; Hergen Spits
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

4.  Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22.

Authors:  Tiffany Hughes; Brian Becknell; Susan McClory; Edward Briercheck; Aharon G Freud; Xiaoli Zhang; Hsiaoyin Mao; Gerard Nuovo; Jianhua Yu; Michael A Caligiuri
Journal:  Blood       Date:  2009-02-24       Impact factor: 22.113

5.  Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.

Authors:  Sofia Buonocore; Philip P Ahern; Holm H Uhlig; Ivaylo I Ivanov; Dan R Littman; Kevin J Maloy; Fiona Powrie
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

6.  CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.

Authors:  Randy S Longman; Gretchen E Diehl; Daniel A Victorio; Jun R Huh; Carolina Galan; Emily R Miraldi; Arun Swaminath; Richard Bonneau; Ellen J Scherl; Dan R Littman
Journal:  J Exp Med       Date:  2014-07-14       Impact factor: 14.307

7.  The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases.

Authors:  Françoise Meylan; Todd S Davidson; Erin Kahle; Michelle Kinder; Krishika Acharya; Dragana Jankovic; Virgilio Bundoc; Marcus Hodges; Ethan M Shevach; Andrea Keane-Myers; Eddie C Y Wang; Richard M Siegel
Journal:  Immunity       Date:  2008-06-19       Impact factor: 31.745

8.  TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.

Authors:  Bhanu P Pappu; Anna Borodovsky; Timothy S Zheng; Xuexian Yang; Ping Wu; Xingwen Dong; Shawn Weng; Beth Browning; Martin L Scott; Li Ma; Lihe Su; Qiang Tian; Pascal Schneider; Richard A Flavell; Chen Dong; Linda C Burkly
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

9.  Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation.

Authors:  Lei Fang; Becky Adkins; Vadim Deyev; Eckhard R Podack
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

10.  The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells.

Authors:  F Meylan; E T Hawley; L Barron; J L Barlow; P Penumetcha; M Pelletier; G Sciumè; A C Richard; E T Hayes; J Gomez-Rodriguez; X Chen; W E Paul; T A Wynn; A N J McKenzie; R M Siegel
Journal:  Mucosal Immunol       Date:  2013-12-25       Impact factor: 7.313

View more
  17 in total

1.  LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection.

Authors:  Goo-Young Seo; Jr-Wen Shui; Daisuke Takahashi; Christina Song; Qingyang Wang; Kenneth Kim; Zbigniew Mikulski; Shilpi Chandra; Daniel A Giles; Sonja Zahner; Pyeung-Hyeun Kim; Hilde Cheroutre; Marco Colonna; Mitchell Kronenberg
Journal:  Cell Host Microbe       Date:  2018-08-08       Impact factor: 21.023

2.  Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.

Authors:  Jim G Castellanos; Viola Woo; Monica Viladomiu; Gregory Putzel; Svetlana Lima; Gretchen E Diehl; Andrew R Marderstein; Jorge Gandara; Alexendar R Perez; David R Withers; Stephan R Targan; David Q Shih; Ellen J Scherl; Randy S Longman
Journal:  Immunity       Date:  2018-12-11       Impact factor: 31.745

Review 3.  Innate lymphoid cells link gut microbes with mucosal T cell immunity.

Authors:  Jim G Castellanos; Randy S Longman
Journal:  Gut Microbes       Date:  2019-07-26

4.  Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis.

Authors:  Wangdong Xu; Linchong Su; Pingying Qing; Ying Wang; Yan Liang; Yi Zhao; Qiongxiu Zhou; Feng Ma; Yi Liu
Journal:  Clin Rheumatol       Date:  2017-04-10       Impact factor: 2.980

Review 5.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

6.  The TNF family member TL1A induces IL-22 secretion in committed human Th17 cells via IL-9 induction.

Authors:  Lisa S Thomas; Stephan R Targan; Masato Tsuda; Qi T Yu; Brenda C Salumbides; Talin Haritunians; Emebet Mengesha; Dermot P B McGovern; Kathrin S Michelsen
Journal:  J Leukoc Biol       Date:  2016-10-12       Impact factor: 6.011

7.  Reduced monocyte and macrophage TNFSF15/TL1A expression is associated with susceptibility to inflammatory bowel disease.

Authors:  Arianne C Richard; James E Peters; Natalia Savinykh; James C Lee; Eric T Hawley; Françoise Meylan; Richard M Siegel; Paul A Lyons; Kenneth G C Smith
Journal:  PLoS Genet       Date:  2018-09-10       Impact factor: 5.917

Review 8.  TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.

Authors:  Vassilis Valatas; George Kolios; Giorgos Bamias
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

9.  A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.

Authors:  Li-Guo Jia; Giorgos Bamias; Kristen O Arseneau; Linda C Burkly; Eddy C Y Wang; Dennis Gruszka; Theresa T Pizarro; Fabio Cominelli
Journal:  J Immunol       Date:  2016-05-27       Impact factor: 5.422

10.  Modulation of Intestinal ILC3 for the Treatment of Type 1 Diabetes.

Authors:  Ivana Stojanović; Tamara Saksida; Đorđe Miljković; Nada Pejnović
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.